Insta
Moderna Says Its COVID-19 Vaccine Showed 96 Per Cent Efficacy In Study On Adolescents Aged Between 12-17 Years
Sophy Ridge (Twitter)
United States (US)-based pharmaceutical major and vaccine maker Moderna has said that the studies of its two-dose mRNA COVID-19 vaccine in teenagers has shown an efficacy rate of 96 per cent, reports Hindustan Times.
The study was conducted among adolescent participants from the age group of 12-17 years. The company claims that the vaccine has shown no serious safety problems and that it will ll build up its production capacity to boost the supplies of its vaccine.
The company has also recently released the results of preliminary human trials showing that two types of booster shots of its vaccine helped bolster immune responses against variants that surfaced in South Africa and Brazil.
The company had recently announced investments in its US plants and overseas contractors to raise the production to as much as three billion doses next year.
Moderna Inc's vaccine is already being widely used in the US for inoculation of American adults against COVID-19.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
